Skip to content

No Axillary sUrgical Treatment In clinically Lymph node negative patients after UltraSonography[NAUTILUS]: A Prospective, Multicenter, phase III Clinical Trial

No Axillary sUrgical Treatment In clinically Lymph node negative patients after UltraSonography[NAUTILUS]: A Prospective, Multicenter, phase III Clinical Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CRIS
Registry ID
KCT0004840
Enrollment
1734
Registered
2020-03-20
Start date
2020-05-01
Completion date
Unknown
Last updated
2020-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Procedure/Surgery : The study arm gets breast conserving surgery performed, while the control arm gets both breast conserving surgery and sentinel lymph node biopsy performed. Additional surgical proc

Sponsors

Seoul National University Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: • Women = 19 years • Invasive unilateral breast carcinoma with histological confirmation • History of invasive breast cancer • Histologically or radiologically no suspicion of distant metastases • Performance status corresponding to ECOG grade 0-2 • Tumor size clinically and radiologically = 5cm, independent of hormone receptor and HER2 status • Clinically and sonographically negative axillary lymph nodes before biopsy; core needle biopsy or fine needle aspiration of suspicious lymph node required • BCS candidate with postoperative whole-breast irradiation and adequate systemic therapy • No psychological and geographical restriction in follow-up • Written informed consent

Exclusion criteria

Exclusion criteria: • History of any cancer in the previous 5 years • Bilateral breast cancer • Invasive breast cancer treated with neoadjuvant therapy • Tumor size clinically and radiologically > 5cm • Mastectomy candidate • Pregnancy and breastfeeding • Male breast cancer • Unable to understand and fill out questionnaires

Design outcomes

Primary

MeasureTime frame
5yr Invasive Disease Free Survival

Secondary

MeasureTime frame
5yr Overall Survival;5yr Distant Metastasis Free Survival;Axilla Recurrence;5yr Locoregional Recurrence Rate;Adverse Events;Quality of Life

Countries

Korea, Republic of

Contacts

Public ContactJi Gwang Jung

Seoul National University Hospital

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026